TMO vs TT
Thermo Fisher Scientific Inc. and Trane Technologies PLC, side by side — 10 fiscal years reported in USD, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | TMO | TT |
|---|---|---|
| Revenue | $44.6B | $21.3B |
| Net income | $6.7B | $2.9B |
| Gross margin | 57.1% | 30.5% |
| Net margin | 15.0% | 13.7% |
| Return on equity | 13.0% | 36.4% |
| Diluted EPS | $17.74 | $12.98 |
| Dividend / share | $1.72 | $3.76 |
| Payout ratio | 9.5% | 28.7% |
| Free cash flow | $6.3B | $2.8B |
| Equity | $53.4B | $8.6B |
| Net debt / equity | 0.62× | 0.33× |
| Current ratio | 1.89× | 1.25× |
| Revenue CAGR 5y | 6.7% | 11.4% |
| Profit CAGR 5y | 1.0% | 27.8% |
TMO bills 2.1× the revenue of TT, and keeps more of each dollar of revenue as profit (15.0% against 13.7%).
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Advertisement
AdSense · Leaderboard 728×90 · responsive
Revenue by year
10 years side by side
| Fiscal year | TMO | TT |
|---|---|---|
| FY2025 | $44.6B | $21.3B |
| FY2024 | $42.9B | $19.8B |
| FY2023 | $42.9B | $17.7B |
| FY2022 | $44.9B | $16.0B |
| FY2021 | $39.2B | $14.1B |
| FY2020 | $32.2B | $12.5B |
| FY2019 | $25.5B | $13.1B |
| FY2018 | $24.4B | $12.3B |
| FY2017 | $20.9B | $14.2B |
| FY2016 | $18.3B | $13.5B |
Net income by year
Bottom line
| Fiscal year | TMO | TT |
|---|---|---|
| FY2025 | $6.7B | $2.9B |
| FY2024 | $6.3B | $2.6B |
| FY2023 | $6.0B | $2.0B |
| FY2022 | $7.0B | $1.8B |
| FY2021 | $7.7B | $1.4B |
| FY2020 | $6.4B | $854.9M |
| FY2019 | $3.7B | $1.4B |
| FY2018 | $2.9B | $1.3B |
| FY2017 | $2.2B | $1.3B |
| FY2016 | $2.0B | $1.5B |
Advertisement
AdSense · Rectangle 336×280